Sec Form 13G Filing - Antara Capital LP @ Revance Therapeutics Inc.

Sec Form 13G Filing - Antara Capital LP filing for Revance Therapeutics Inc. (RVNC) - 2023-02-14

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Amendment No. )

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

Revance Therapeutics, Inc.

(Name of Issuer)

Common Stock, $.001 par value

(Title of Class of Securities)

761330109

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒	Rule 13d-1(b)

☐	Rule 13d-1(c)

☐	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 761330109


*		SEE INSTRUCTIONS BEFORE FILLING OUT
**		SEE ITEM 4.

CUSIP No. 761330109


*		SEE INSTRUCTIONS BEFORE FILLING OUT
**		SEE ITEM 4.

CUSIP No. 761330109


*		SEE INSTRUCTIONS BEFORE FILLING OUT
**		SEE ITEM 4.

SCHEDULE 13G

Item 1(a)

Name of Issuer.

Revance Therapeutics, Inc. (the “Issuer”)

Item 1(b)

Address of Issuer’s Principal Executive Offices.

1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203

Item 2(a)

Name of Person Filing.

This Schedule 13G is being filed by

(i)	Antara Capital LP (“Antara Capital”)

(ii)	Antara Capital GP LLC (“Antara GP”)

(iii)

Himanshu Gulati (“Mr. Gulati”)

Item 2(b)

Address of Principal Business Office, or, if none, Residence.

The principal business address of each of the Reporting Persons is:

55 Hudson Yards, 47^th Floor, Suite C

New York, NY 10001

Item 2(c)

Citizenship or Place of Organization.

(i)	Antara Capital is a Delaware limited partnership

(ii)	Antara GP is a Delaware limited liability company

(iii)

Mr. Gulati is an individual and is a citizen of the United States.

Item 2(d)

Title of Class of Securities.

Common Stock, $.001 par value (the “Common Stock”).

Item 2(e)

CUSIP Number.

761330109

Item 3

Reporting Person.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Exchange Act.

(b)	☐	Bank as defined in section 3(a)(6) of the Exchange Act.

(c)	☐	Insurance company as defined in section 3(a)(19) of the Exchange Act.

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940.

(e)	☒	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

(g)	☒	A parent holding company or control person in accordance with Rule 13d 1(b)(1)(ii)(G).

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

(j)	☐	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4

Ownership.

Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference.

Antara Capital Master Fund LP (“Antara Master Fund”) holds options to purchase 5,077,300 shares of Common Stock. A certain managed account for which Antara Capital serves as investment manager (the “Managed Account”) holds options to purchase 162,300 shares of Common Stock.

The Reporting Persons in the aggregate beneficially own approximately 6.4% of the shares of Common Stock, based on 82,273,582 shares of Common Stock of the Issuer outstanding as of October 31, 2022, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2022.

Antara Capital is the investment manager of the Antara Master Fund and the Managed Account. Antara GP is the general partner of Antara Capital. Mr. Gulati is the sole member of Antara GP. Antara Capital, Antara GP and Mr. Gulati may be deemed to beneficially own the securities of the Issuer held directly by Antara Master Fund and the Managed Account.

Item 5

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

Item 6

Ownership of More Than Five Percent on Behalf of Another Person.

The shares of Common Stock beneficially owned by the Reporting Persons are directly held by Antara Master Fund and the Managed Account, for which Antara Capital LP serves as investment manager.

Item 7

Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

Not applicable.

Item 8

Identification and Classification of Members of the Group.

Not applicable.

Item 9

Notice of Dissolution of Group.

Not applicable.

Item 10

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2023


ANTARA CAPITAL LP

By:		Antara Capital GP LLC, its general partner

By:		/s/ Himanshu Gulati
		Name: Himanshu Gulati Title: Managing Member

ANTARA CAPITAL GP LLC

By:		/s/ Himanshu Gulati
		Name: Himanshu Gulati Title: Managing Member

By:		/s/ Himanshu Gulati
		Name: Himanshu Gulati Title: Managing Member

EXHIBIT LIST


Exhibit 99.1		Joint Filing Agreement, dated as of February 14, 2023, by and among Antara Capital LP, Antara Capital GP LLC and Himanshu Gulati.

NAME OF REPORTING PERSONS

Antara Capital LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware